Harvard Apparatus Regenerative Technology, Inc. (HART) is “One to Watch”

Harvard Apparatus achieved considerable buzz this morning in announcing significant results from animal research on its second-generation bioengineered platform. Demonstrating clear evidence of complete esophageal tissue regeneration within two weeks, the study “far exceeded” company – and market, so it seems – expectations.

“We pursued these animal studies to test the design and technology enhancements we have made to our second generation technology and to prepare us for our upcoming studies with the Mayo Clinic. We are very encouraged by the results of these studies and by the significant advancements we have made across all three indications …,” HART CEO Jim McGorry said in today’s news release.

Company chief Medical Officer Saverio La Francesca, M.D. added to the sentiment, stating that “We believe that our second generation implant possesses all the necessary cues to elicit full regeneration of the esophagus. Importantly, our esophageal implant addresses a very significant need as a potentially life-saving treatment for patients with esophageal cancer. Each year in the U.S. approximately 17,000 new cases of esophageal cancer are diagnosed, and more than 4,000 are addressed by surgery. Our results underscore the value and potential of our platform technology to treat these patients and pave the way for further studies and our regulatory pathway for human clinical trials.”

McGorry has been at his executive post for four months now, and moving forward will guide the company through expanded preclinical trials at the Mayo Clinic slated for December. HART plans to file an initial IND application with the USDA next year.

Today’s news boosted shares more than 115% in mid-day trading, a welcome increase considering the company earlier this week received a delisting notice from NASDAQ. The company’s stock is down 89% since the start of the year.

If that’s enough to pique your interest, join in on the company’s conference call at 5 p.m. ET today for a discussion of study results. Dial toll-free 877-407-8293, or international: 201-689-8349, and reference Harvard Apparatus Regenerative Technology, Inc. You can also access the audio webcast at http://public.viavid.com/index.php?id=117087.

A replay will be available within approximately three hours from the end of the call through 11:59 pm ET on November 19, 2015, and will be accessible by dialing toll-free 877-660-6853, or toll/international 201-612-7415, and referencing conference ID “13624147.” The replay will also be made available at the web link above and on the company’s web site, www.harvardapparatusregen.com.

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net